Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD5153 6-Hydroxy-2-naphthoic acid (AZD5153) 是 AZD5153的6-羟基-2-萘甲酸盐形式。AZD5153是一种有口服活性的选择性 BET/BRD4溴结构域抑制剂,对BRD4的IC50值为1.7nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 421 | 现货 | ||
5 mg | ¥ 926 | 现货 | ||
10 mg | ¥ 1,610 | 现货 | ||
25 mg | ¥ 3,130 | 现货 | ||
50 mg | ¥ 4,590 | 现货 | ||
100 mg | ¥ 6,580 | 现货 | ||
500 mg | ¥ 13,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,430 | 现货 |
产品描述 | AZD5153 6-Hydroxy-2-naphthoic acid (AZD5153) is a potent triazolopyridazine-based Bromodomain (BRD4) and Extraterminal (BET) inhibitor used in cancer treatments. |
靶点活性 | FL-BRD4:5 nM |
体外活性 | AZD5153 treatment markedly affects transcriptional programs of MYC, E2F, and mTOR. Of note, mTOR pathway modulation is associated with cell line sensitivity to AZD5153. AZD5153 potently disrupts BRD4 foci in U2OS cells with an IC50 value of 1.7 nmol/L. AZD5153 efficiently downregulates MYC protein levels across the cell line panel irrespective of their sensitivity to AZD5153. AML, MM, and DLBCL cell lines are highly sensitive to AZD5153. |
体内活性 | AZD5153 modulates MYC and HEXIM1 in AML xenograft tumors and human whole blood. In vivo administration of AZD5153 leads to tumor stasis or regression in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B-cell lymphoma. AZD5153 is administered orally to mice bearing MV-4-11 xenografts, and pharmacodynamic activity (intratumoral levels of c-Myc) is measured at 2, 4, and 8 h postdose. A considerable decrease in c-Myc expression is observed out to 8 h post dose at free plasma levels of compound <0.2 μM. This decrease in c-Myc expression after treatment with AZD5153 is consistent with other published BET inhibitors. |
细胞实验 | Apoptosis was analyzed by flow cytometry using CellEvent Caspase 3/7 Green detection reagent. MV-4-11, MM.1S, and K562 cells were pretreated with AZD5153 or I-BET762 for 48 hours in culture media. Cells were collected and stained with 5 μmol/L final concentration of CellEvent for 30 minutes at 37°C. Flow cytometry was done on a BD Fortessa using the Blue laser and FITC filter set. (Only for Reference) |
别名 | AZD5153, AZD5153结晶体(API形式), AZD-5153 HNT salt |
分子量 | 667.75 |
分子式 | C25H33N7O3·C11H8O3 |
CAS No. | 1869912-40-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 26 mg/mL (38.9 mM)
DMSO: 93 mg/mL (139.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.4976 mL | 7.4878 mL | 14.9757 mL | 37.4392 mL |
5 mM | 0.2995 mL | 1.4976 mL | 2.9951 mL | 7.4878 mL | |
10 mM | 0.1498 mL | 0.7488 mL | 1.4976 mL | 3.7439 mL | |
20 mM | 0.0749 mL | 0.3744 mL | 0.7488 mL | 1.872 mL | |
DMSO | 50 mM | 0.03 mL | 0.1498 mL | 0.2995 mL | 0.7488 mL |
100 mM | 0.015 mL | 0.0749 mL | 0.1498 mL | 0.3744 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD5153 6-Hydroxy-2-naphthoic acid 1869912-40-2 Chromatin/Epigenetic Epigenetic Reader Domain AZD5153 AZD-5153 AZD5153结晶体(API形式) AZD-5153 HNT AZD5153 6 Hydroxy 2 naphthoic acid Inhibitor AZD-5153 HNT salt AZD5153 6Hydroxy2naphthoic acid AZD 5153 inhibit AZD-5153 6-Hydroxy-2-naphthoic acid inhibitor